# Diabetes Research Hub — Daily Monitor Report
**Date:** 2026-04-13 (Monday) | **Run:** #24

---

## File System Status

| File | Last Modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-04-13 07:05 | Fresh (today) |
| clinical_trials_latest.json | 2026-04-13 07:05 | Fresh (today) |
| pubmed_recent_latest.json | 2026-04-13 07:05 | Fresh (today) |
| literature_gap_data.json | 2026-04-03 09:31 | Stale (10 days) |
| literature_gap_report.md | 2026-04-12 14:06 | OK |
| clinical_trials_snapshot_2026-04-13.json | 2026-04-13 | Fresh (today) |
| pubmed_recent_snapshot_2026-04-13.json | 2026-04-13 | Fresh (today) |

**Total files tracked:** 699 (3 new, 29 modified, 0 removed since yesterday)

**Note:** 367 result files are older than 14 days and may need refresh. The literature_gap_data.json is 10 days old — consider re-running the gap analysis soon.

---

## Clinical Trial Changes

### Snapshot Diff (Apr 12 → Apr 13)
- New trials: **0**
- Removed trials: **0**
- Status changes: **0**
- New results posted: **0**

No changes in the trial landscape since yesterday. The database holds **758 total trials** across 5 categories:

| Category | Count |
|----------|-------|
| Diabetes Technology (Devices) | 219 |
| Diabetes Recently Completed with Results | 255 |
| T1D Cure & Cell Therapy | 151 |
| T2D Novel Therapies (Phase 2-3) | 137 |
| T1D Immunotherapy & Prevention | 71 |

### Key Phase 3 Trials — Active & Recruiting

These are the highest-priority trials to watch:

| NCT ID | Trial | Sponsor | Status |
|--------|-------|---------|--------|
| NCT04786262 | VX-880 in Type 1 Diabetes | **Vertex Pharmaceuticals** | RECRUITING |
| NCT06832410 | VX-880 in T1D with Kidney Transplant | **Vertex Pharmaceuticals** | RECRUITING |
| NCT07222332 | Baricitinib to Preserve Beta Cell Function (BARICADE-PRESERVE) | **Eli Lilly** | RECRUITING |
| NCT07222137 | Baricitinib for Delay of Stage 3 T1D | **Eli Lilly** | RECRUITING |
| NCT05929079 | Retatrutide (LY3437943) in T2D with Obesity | **Eli Lilly** | ACTIVE_NOT_RECRUITING |
| NCT06962280 | Tirzepatide in T1D with Obesity/Overweight | **Eli Lilly** | ACTIVE_NOT_RECRUITING |
| NCT07076199 | Insulin Icodec (weekly) in T1D | **Novo Nordisk** | RECRUITING |
| NCT07220759 | Cagrilintide for Weight Loss in T2D | **Novo Nordisk** | ACTIVE_NOT_RECRUITING |
| NCT05018585 | Diamyd (GAD-alum) in new-onset T1D | Diamyd Medical AB | ACTIVE_NOT_RECRUITING |
| NCT06894784 | Semaglutide + Empagliflozin + AID in T1D | McGill University | RECRUITING |
| NCT06630585 | GIP/GLP-1RA + Automated Insulin Delivery in T1D | University of Bern | RECRUITING |
| NCT07258394 | Dimethyl Fumarate for beta-cell preservation in T1D | Nanjing Medical U | RECRUITING |
| NCT06217302 | Sotagliflozin for DKD in T1D | Alessandro Doria | RECRUITING |

**Sana Biotechnology:** No trials in ClinicalTrials.gov dataset. Per yesterday's report (Run #23), SC451 IND filing is still expected 2026; 14-month UP421 follow-up data (hypoimmune islets survive without immunosuppression) published March 2026. Monitor monthly.

### Trials with Posted Results
256 trials have posted results (primarily in the "Recently Completed" category). No new results posted since last check.

---

## PubMed Highlights

### Snapshot Diff (Apr 12 → Apr 13)
- **19 new papers** entered the 30-day window
- **18 papers** dropped out (rolling window)
- **129 unique papers** currently tracked across 15 alert domains

### Cross-Domain Papers (Highest Priority)

These papers span multiple alert domains and represent cross-disciplinary work:

| PMID | Title | Domains | Journal |
|------|-------|---------|---------|
| 41889910 | Donor-derived CD8+ T cells for mixed chimerism in T1D | T1D Stem Cell Cure + T1D Immunotherapy | bioRxiv |
| 41958643 | Role of immunology in microbiome-diabetes interaction | T1D Immunotherapy + Diabetes Microbiome | Frontiers in Immunology |
| 41961886 | Predicted meta-omics for microbiome studies | Diabetes AI/ML + Diabetes Microbiome | PLoS ONE |
| 41962267 | Network pharmacology + multi-omics for MASLD via fatty acid metabolism | Diabetes Biomarker + Diabetes Multi-Omics | Phytomedicine |
| 41952284 | LncRNA H19 as diagnostic/therapeutic target for kidney diseases | Diabetes Biomarker + Diabetes Complications | Cell Biochemistry & Function |
| 41955563 | Text messaging to transition basal insulin → GLP-1 RA in safety-net care | T2D GLP-1 New + Diabetes Health Equity | JMIR Formative Research |

**Action items:**
- PMID 41889910 (mixed chimerism + CD8 T cells) is directly relevant to islet transplant tolerance — review for Research Path connections
- PMID 41955563 (GLP-1 transition in safety-net) bridges health equity and novel therapies — relevant to Gap #12 (Drug Repurposing × Health Equity)

### Key Therapy Mentions

| Therapy | Found? | Details |
|---------|--------|---------|
| Teplizumab | Yes | PMID 41913320 — "Toward Personalized Medicine in T1D" (Diabetes, Obesity & Metabolism). Reviews heterogeneity in patient response to teplizumab. |
| Baricitinib | No | (But 2 Lilly Phase 3 trials actively recruiting — see Clinical Trials section) |
| Orforglipron | No | No recent PubMed papers in 30-day window |
| Retatrutide | No | Phase 3 trial NCT05929079 active but no new pubs |
| CagriSema | No | Phase 3 trial NCT07220759 active but no new pubs |
| Zimislecel | No | No mentions |

### Domain Activity (30-day window)

**Highest activity:**
- Diabetes AI/ML: 162 papers (very active)
- T2D GLP-1 New: 145 papers
- Diabetes Microbiome: 134 papers
- Diabetes Biomarker: 113 papers

**Lowest activity:**
- LADA New Research: 3 papers (chronically low — aligns with gap analysis showing LADA as under-researched)
- Diabetes Drug Repurpose: 4 papers
- Diabetes Epigenetics: 9 papers

---

## Gap Analysis Summary

**Data age:** Generated 2026-04-03 (10 days old). Methodology is sound (geometric mean normalization). All classifications rated BRONZE confidence.

### Top 5 Meaningful Research Gaps

| Rank | Domain Pair | Gap Score | Joint Pubs | Relevance to Our Work |
|------|-------------|-----------|------------|----------------------|
| 1 | Beta Cell Regen × Health Equity | 100.0 | 0 | Aligns with Contribution Strategy: equity analysis of emerging cell therapies |
| 2 | Insulin Resistance × Islet Transplant | 100.0 | 1 | Relevant to islet transplant research paths |
| 3 | Islet Transplant × Drug Repurposing | 100.0 | 0 | **Directly aligns with Project 4 (Drug Repurposing Screen)** — computational screening for islet-protective drugs is our Tier 1 niche |
| 4 | Islet Transplant × Health Equity | 100.0 | 0 | Access equity for cell therapies — complements Gap #1 |
| 5 | Gene Therapy × LADA | 100.0 | 0 | LADA's autoimmune mechanism makes it a gene therapy candidate; unexplored |

**Tier 1 alignment:** Gaps #2 and #3 (Islet Transplant × Insulin Resistance, Islet Transplant × Drug Repurposing) directly align with our active research paths in islet drug repurposing. The existing `islet_repurposing_report.md` and `islet_repurposing_drug_candidates.json` should be cross-referenced with these gap findings.

---

## Breaking News (Web Search — April 7-13, 2026)

### FDA Actions

| Event | Date | Significance |
|-------|------|-------------|
| **Awiqli (insulin icodec) FDA approval** | March 2026 | First-ever once-weekly basal insulin for T2D. Novo Nordisk. Phase 3 trial NCT07076199 now testing in T1D. |
| **Generic dapagliflozin approved** | April 2026 | First generics of Farxiga approved for HF risk reduction in T2D + glycemic control. Increases SGLT2i access. |
| **Generic dapagliflozin-metformin combo** | April 8, 2026 | Lupin received FDA approval. Lower-cost combination for T2D management. |
| **Oral semaglutide (Wegovy 25mg)** | Early 2026 | First GLP-1 pill for weight loss launched in US. |

### Research News

- **MUSC / Breakthrough T1D:** $1M grant for two-part T1D cure strategy — lab-made insulin-producing cells paired with custom-engineered immune cells for protection. Early stage but aligns with our T1D Cure & Cell Therapy tracking.
- **ADA Standards of Care 2026:** Now recommends CGM at diabetes onset. Also highlights AI for early T1D risk prediction.
- **ATTD 2026 Conference:** Reported breakthroughs in T1D technology and treatment integration (details from Days 3-4 coverage by Breakthrough T1D).

**Assessment:** The generic dapagliflozin approval is noteworthy for our SGLT2i research paths — increased access may generate new real-world evidence. The Awiqli approval feeds into the insulin icodec T1D trial we're already tracking (NCT07076199).

---

## Work Queue Status (from Run #23)

Items processed yesterday:
1. Sana Biotechnology SC451 — priority lowered to 5, monitor monthly
2. DAPAN-DIA Trial NCT06047262 — Phase 2 recruiting, monitor quarterly
3. AZD1656 ADOPTION Trial — ongoing, monitor quarterly
4. SGLT2i + Colchicine — **NEW FINDING** PMID 40907678 (TriNetX retrospective, 12,235 matched patients, significant MACE reduction). Added as UNVETTED. Vetting queued.

**Papers:** 244 vetted + 1 unvetted (PMID 40907678). **Research Paths:** 8 total (7 validated, 1 partially validated). **Work Queue:** 15 items remaining.

**Pipeline Status:** All 39 improvement scripts passed. Credibility sweep clean.

---

## Recommended Actions

### Immediate (this week)
1. **Vet PMID 40907678** (SGLT2i + colchicine combo) — retrospective data showing significant MACE reduction. If validated, this connects to our dapagliflozin inflammation research path.
2. **Review cross-domain paper PMID 41889910** (mixed chimerism + CD8 T cells) — directly relevant to islet transplant tolerance research paths.
3. **Review PMID 41913320** (teplizumab personalized medicine) — relevant to our teplizumab sNDA decision prep file.

### Soon (next 1-2 weeks)
4. **Re-run gap analysis** — `literature_gap_data.json` is 10 days old. Run: `python project1_literature_gap_analysis.py`
5. **Update tracker** with Awiqli FDA approval (March 2026) and generic dapagliflozin approval (April 2026) as relevant milestones.
6. **Review PMID 41955563** (GLP-1 transition in safety-net care) — bridges health equity and novel therapies, aligns with our identified Gap #12.

### Ongoing
7. **Monitor Sana Biotechnology SC451** IND filing — expected 2026, check monthly.
8. **Monitor DAPAN-DIA (NCT06047262)** and AZD1656 ADOPTION trials — check quarterly.
9. **Address 367 stale files** (>14 days old) in Analysis/Results/ — prioritize refreshing files tied to active research paths.

---

---

## Actions Taken (Run #24 Follow-Up)

### Tracker Updated
- Added 4 FDA milestone rows to Therapy Pipeline sheet (rows 74-77):
  - Awiqli (insulin icodec) — first weekly basal insulin, FDA approved March 2026
  - Generic dapagliflozin — first Farxiga generics, FDA approved April 2026
  - Generic dapagliflozin-metformin — Lupin, FDA approved April 8, 2026
  - Oral semaglutide 25mg (Wegovy) — first oral GLP-1 for weight loss, launched Jan 2026
- Added 4 papers to Paper Tracker (rows 41-44)

### Paper Vetting Completed

**PMID 40907678 — SGLT2i + Colchicine Combo**
- **Vetting status: PARTIALLY_VALIDATED**
- **Evidence level: MODERATE (observational only)**
- Strengths: Large matched cohort (12,235/arm), consistent benefit across endpoints, biologically plausible
- Limitations: Retrospective TriNetX design, no prospective RCT registered, residual confounding risk
- Action: Suitable for hypothesis generation. Flag for clinicians that combo effect is unproven in prospective trials.

### Cross-Domain Paper Reviews

| PMID | Verdict | Action |
|------|---------|--------|
| 41889910 | Mixed chimerism + CD8 T cells — could not verify full details (very recent preprint) | Needs manual PubMed check |
| 41961886 | **HIGH relevance** — ML models predicting metabolite abundances from metagenomics (r=0.74-0.77) | **Added to Paper Tracker** — directly enables microbiome-ML pipeline |
| 41913320 | **HIGH relevance** — Identifies exhausted T-cell phenotypes predicting teplizumab response | **Added to Paper Tracker** — essential for teplizumab decision prep |
| 41955563 | **MEDIUM-HIGH** — SMS program for insulin→GLP-1 transition in safety-net clinics | **Added to Paper Tracker** — bridges health equity + novel therapies |
| 41952284 | MEDIUM — LncRNA H19 in diabetic kidney fibrosis | Monitor only, not core to active paths |
| 41958643 | Immunology-microbiome bridge — could not verify full details | Needs manual PubMed check |
| 41962267 | Network pharmacology + multi-omics for MASLD — peripheral relevance | Monitor only |

### Gap Analysis Refresh
- **Attempted** to re-run `project1_literature_gap_analysis.py` in the sandbox
- Script queries PubMed for all 435 domain pairs — exceeded sandbox timeout (45s)
- **You'll need to run this locally:** `cd Analysis/Scripts && python project1_literature_gap_analysis.py`
- Also recommended: `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py`

---

*Generated by Diabetes Research Hub automated monitor — 2026-04-13*
*Previous report: monitor_report_2026-04-12.md (Run #23)*
